노인황반변성 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 유형별, 질환 단계별, 치료법별, 판매 채널별, 지역별, 경쟁별 세분화(2020-2030년)
Macular Degeneration Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Stage of Disease, By Treatment Type, By Sales Channel, By Region, By Competition 2020-2030F
상품코드:1886360
리서치사:TechSci Research
발행일:2025년 12월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 황반변성 치료 시장은 2024년 141억 9,000만 달러에서 2030년까지 229억 달러로, CAGR 8.30%로 성장할 것으로 예측됩니다. 황반변성 치료에는 주로 항혈관내피성장인자(항VEGF)를 비롯한 다양한 약물요법과 함께 노화성 황반변성(AMD)을 관리하기 위한 기타 보조요법이 포함됩니다. AMD는 진행성 안질환으로 중심 시력 상실을 유발하는 질환입니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
141억 9,000만 달러
시장 규모 : 2030년
229억 달러
CAGR : 2025-2030년
8.30%
가장 빠르게 성장하는 부문
노인황반변성(습성형)
최대 시장
북미
주요 시장 성장 촉진요인
세계 황반변성 유병률 증가와 치료법 및 의약품 개발의 지속적인 발전으로 인해 세계 황반변성 치료제 시장은 크게 성장하고 있습니다. 노화성 황반변성 발생률이 증가함에 따라 효과적인 치료법을 필요로 하는 환자 수가 증가하고 있습니다.
주요 시장 과제
장기적인 치료 요법, 특히 항혈관내피성장인자(항VEGF)의 반복적인 초자체내 투여에 따른 막대한 경제적 부담은 세계 황반변성 치료제 시장의 성장을 직접적으로 저해하고 있습니다. 이러한 재정적 부담은 환자가 필요한 치료를 받을 수 있는 기회를 제한하고, 각 지역의 의료 예산에 큰 압박을 가하는 심각한 장벽이 되고 있습니다.
주요 시장 동향
건성 노인황반변성(AMD)에 대한 보완체계 억제제 개발은 미충족 의료 수요를 충족시킬 수 있는 중요한 성장 동향입니다. 건성 AMD의 진행형인 지역적 위축의 경우, 지금까지 승인된 질환 개선 치료제가 없었습니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 노인황반변성 치료 시장 전망
시장 규모·예측
금액별
시장 점유율·예측
유형별(건성 노인황반변성, 습성 노인황반변성)
질환 단계별(초기 AMD, 중간기 AMD, 후기 AMD)
치료법별(약제, 의료기기, 외과수술)
판매 채널별(외래 수술 센터, 병원, 기타)
지역별
기업별(2024)
시장 맵
제6장 북미의 노인황반변성 치료 시장 전망
시장 규모·예측
시장 점유율·예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 노인황반변성 치료 시장 전망
시장 규모·예측
시장 점유율·예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 노인황반변성 치료 시장 전망
시장 규모·예측
시장 점유율·예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 노인황반변성 치료 시장 전망
시장 규모·예측
시장 점유율·예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트
남아프리카공화국
제10장 남미의 노인황반변성 치료 시장 전망
시장 규모·예측
시장 점유율·예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
촉진요인
과제
제12장 시장 동향과 발전
합병·인수
제품 출시
최근 동향
제13장 세계의 노인황반변성 치료 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
PanOptica Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Aerie Pharmaceutical Inc.
REGENXBIO Inc.
Bayer AG
Lineage Cell Therapeutics Inc
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Macular Degeneration Treatment Market will grow from USD 14.19 Billion in 2024 to USD 22.90 Billion by 2030 at a 8.30% CAGR. Macular degeneration treatments encompass a range of pharmacological interventions, primarily anti-vascular endothelial growth factor (anti-VEGF) agents, along with other supportive therapies designed to manage age-related macular degeneration (AMD), a progressive ophthalmic condition leading to central vision loss.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 14.19 Billion
Market Size 2030
USD 22.90 Billion
CAGR 2025-2030
8.30%
Fastest Growing Segment
Wet Age-related Macular Degeneration
Largest Market
North America
Key Market Drivers
The global macular degeneration treatment market is significantly propelled by the increasing worldwide prevalence of age-related macular degeneration and continuous advancements in therapeutic modalities and drug development. The rising incidence of AMD creates an expanding patient pool demanding effective interventions. For instance, according to Eye Health Central, in 2025, approximately 200 million people worldwide are living with some form of age-related macular degeneration, underscoring the vast and growing clinical need that drives market demand.
Key Market Challenges
The substantial economic burden associated with long-term treatment regimens, particularly the recurring intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents, directly hampers the growth of the global macular degeneration treatment market. This financial strain presents a significant barrier, limiting patient access to necessary therapies and placing considerable pressure on healthcare budgets across various regions. The chronic nature of age-related macular degeneration (AMD) necessitates ongoing treatment, often involving frequent injections, which accumulates substantial costs over time for individuals and health systems.
Key Market Trends
The development of complement system inhibitors for dry age-related macular degeneration (AMD) represents a significant growth trend, addressing a substantial unmet medical need. Geographic atrophy, an advanced form of dry AMD, previously lacked approved disease-modifying therapies. These novel inhibitors target specific components of the complement cascade, an immune pathway implicated in dry AMD's pathogenesis and progression. Such targeted treatments offer the potential to slow disease progression and preserve vision.
Key Market Players
F. Hoffmann-La Roche Ltd
Novartis AG
Pfizer Inc.
PanOptica Inc.
Bausch Health Companies Inc.
Regeneron Pharmaceuticals Inc.
Aerie Pharmaceutical Inc.
REGENXBIO Inc.
Bayer AG
Lineage Cell Therapeutics Inc
Report Scope:
In this report, the Global Macular Degeneration Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Macular Degeneration Treatment Market, By Type:
Dry Age-related Macular Degeneration
Wet Age-related Macular Degeneration
Macular Degeneration Treatment Market, By Stage of Disease:
Early-stage AMD
Intermediate AMD
Late-stage AMD
Macular Degeneration Treatment Market, By Treatment Type:
Drug
Devices
Surgery
Macular Degeneration Treatment Market, By Sales Channel:
Ambulatory Surgical Centers
Hospitals
Other
Macular Degeneration Treatment Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Macular Degeneration Treatment Market.
Available Customizations:
Global Macular Degeneration Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Macular Degeneration Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration)
5.2.2. By Stage of Disease (Early-stage AMD, Intermediate AMD, Late-stage AMD)
5.2.3. By Treatment Type (Drug, Devices, Surgery)
5.2.4. By Sales Channel (Ambulatory Surgical Centers, Hospitals, Other)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Macular Degeneration Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Stage of Disease
6.2.3. By Treatment Type
6.2.4. By Sales Channel
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Macular Degeneration Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Stage of Disease
6.3.1.2.3. By Treatment Type
6.3.1.2.4. By Sales Channel
6.3.2. Canada Macular Degeneration Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Stage of Disease
6.3.2.2.3. By Treatment Type
6.3.2.2.4. By Sales Channel
6.3.3. Mexico Macular Degeneration Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Stage of Disease
6.3.3.2.3. By Treatment Type
6.3.3.2.4. By Sales Channel
7. Europe Macular Degeneration Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Stage of Disease
7.2.3. By Treatment Type
7.2.4. By Sales Channel
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Macular Degeneration Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Stage of Disease
7.3.1.2.3. By Treatment Type
7.3.1.2.4. By Sales Channel
7.3.2. France Macular Degeneration Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Stage of Disease
7.3.2.2.3. By Treatment Type
7.3.2.2.4. By Sales Channel
7.3.3. United Kingdom Macular Degeneration Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Stage of Disease
7.3.3.2.3. By Treatment Type
7.3.3.2.4. By Sales Channel
7.3.4. Italy Macular Degeneration Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Stage of Disease
7.3.4.2.3. By Treatment Type
7.3.4.2.4. By Sales Channel
7.3.5. Spain Macular Degeneration Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Stage of Disease
7.3.5.2.3. By Treatment Type
7.3.5.2.4. By Sales Channel
8. Asia Pacific Macular Degeneration Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Stage of Disease
8.2.3. By Treatment Type
8.2.4. By Sales Channel
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Macular Degeneration Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Stage of Disease
8.3.1.2.3. By Treatment Type
8.3.1.2.4. By Sales Channel
8.3.2. India Macular Degeneration Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Stage of Disease
8.3.2.2.3. By Treatment Type
8.3.2.2.4. By Sales Channel
8.3.3. Japan Macular Degeneration Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Stage of Disease
8.3.3.2.3. By Treatment Type
8.3.3.2.4. By Sales Channel
8.3.4. South Korea Macular Degeneration Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Stage of Disease
8.3.4.2.3. By Treatment Type
8.3.4.2.4. By Sales Channel
8.3.5. Australia Macular Degeneration Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Stage of Disease
8.3.5.2.3. By Treatment Type
8.3.5.2.4. By Sales Channel
9. Middle East & Africa Macular Degeneration Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Stage of Disease
9.2.3. By Treatment Type
9.2.4. By Sales Channel
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Macular Degeneration Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Stage of Disease
9.3.1.2.3. By Treatment Type
9.3.1.2.4. By Sales Channel
9.3.2. UAE Macular Degeneration Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Stage of Disease
9.3.2.2.3. By Treatment Type
9.3.2.2.4. By Sales Channel
9.3.3. South Africa Macular Degeneration Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Stage of Disease
9.3.3.2.3. By Treatment Type
9.3.3.2.4. By Sales Channel
10. South America Macular Degeneration Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Stage of Disease
10.2.3. By Treatment Type
10.2.4. By Sales Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Macular Degeneration Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Stage of Disease
10.3.1.2.3. By Treatment Type
10.3.1.2.4. By Sales Channel
10.3.2. Colombia Macular Degeneration Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Stage of Disease
10.3.2.2.3. By Treatment Type
10.3.2.2.4. By Sales Channel
10.3.3. Argentina Macular Degeneration Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Stage of Disease
10.3.3.2.3. By Treatment Type
10.3.3.2.4. By Sales Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Macular Degeneration Treatment Market: SWOT Analysis
